一分钟看懂
这是一项关于实体瘤的I 期 / II 期研究，登记的药物或干预包括SMP3124LP，当前状态为招募中。登记地点显示中国Los Angeles、San Francisco、Denver、Celebration等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
SMP3124LP · I 期 / II 期
登记条件中文摘要
年龄范围：18岁及以上
登记的基本范围为不限性别，年龄18岁及以上；以下仅摘录8项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Cedars Sinai Medical Center · Los Angeles
- University of California, San Francisco · San Francisco
- Sarah Cannon Research Institute at HealthOne · Denver
- Advent Health · Celebration
- Northwestern Medicine Cancer Center · Chicago
- The University of Chicago · Chicago
- Ohio State University · Columbus
- SCRI Oncology Partners · Nashville
- Vanderbilt-Ingram Cancer Center · Nashville
- MD Anderson Cancer Center · Houston
- University of Washington · Seattle
- National Cancer Center Hospital East · Kashiwa-shi
- Kyoto University Hospital · Kyoto
入选条件原文摘录
以下为摘录，请打开原始登记查看完整入排标准。
- \- Histologically or cytologically-confirmed cancer that is advanced, recurrent, or metastatic with the following origins, and whose disease progressed on standard therapy and for whom there are no alternative therapies that may confer overall survival benefit.
- For patients in the Dose Escalation part:
- 1. Platinum-resistant ovarian cancer
- Histologically diagnosed ovarian, fallopian tube, or primary peritoneal cancer, with predominantly high-grade (Grade 2 or 3) epithelial features (serous and clear cell)
- Platinum resistant is defined as relapsed within 6 months after the last dose of platinum-based therapy
- 2. Triple negative breast cancer
- ER- and PR-negative with HER2 negative
- HER2 negative is defined as one of the following: 0 or 1+ by IHC, or if IHC 2+, then in situ hybridization is negative per the ASCO-CAP HER2 guidelines
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06526819；登记信息更新于 2026-10-07；本站同步于 2026-10-08，中国中心当前名额未经人工确认。